Brian K P Goh1, Choon-Hua Thng2, Damien M Y Tan3, Albert S C Low4, Jen-San Wong5, Peng-Chung Cheow5, Pierce K H Chow6, Alexander Y F Chung5, Wai-Keong Wong7, London L P J Ooi6. 1. Department of Hepatopancreatobiliary and Transplantation Surgery, Division of Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore; Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore. Electronic address: bsgkp@hotmail.com. 2. Department of Oncologic Imaging, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. 3. Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. 4. Department of Radiology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. 5. Department of Hepatopancreatobiliary and Transplantation Surgery, Division of Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. 6. Department of Hepatopancreatobiliary and Transplantation Surgery, Division of Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore; Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore. 7. Department of General Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
Abstract
BACKGROUND: The Sendai Consensus Guidelines (SCG) were formulated in 2006 to guide the management of mucinous cystic lesions of the pancreas (CLPs) and were updated in 2012 (International Consensus Guidelines, ICG 2012). This study aims to evaluate the clinical utility of the ICG 2012 with the SCG based on initial cross-sectional imaging findings. METHODS: One hundred fourteen patients with mucinous CLPs were reviewed and classified according to the ICG 2012 as high risk (HR(ICG2012)), worrisome (W(ICG2012)), and low risk (LR(ICG2012)), and according to the SCG as high risk (HR(SCG)) and low risk (LR(SCG)). RESULTS: On univariate analysis, the presence of symptoms, obstructive jaundice, elevated serum carcinoembryonic antigen (CEA)/carbohydrate antigen (CA)19-9, solid component, main pancreatic duct ≥ 10 mm, and main pancreatic duct ≥ 5 mm was associated with high grade dysplasia/invasive carcinoma in all mucinous CLPs. Increasing number of HR(SCG) or HR(ICG2012) features was associated with a significantly increased likelihood of malignancy. The positive predictive value of HR(SCG) and HR(ICG2012) for high grade dysplasia/invasive carcinoma was 46% and 62.5% respectively. The negative predictive value of both LR(SCG) and LR(ICG2012) was 100%. CONCLUSION: Both the guidelines were useful in the initial cross-sectional imaging evaluation of mucinous CLPs. The ICG 2012 guidelines were superior to the SCG guidelines.
BACKGROUND: The Sendai Consensus Guidelines (SCG) were formulated in 2006 to guide the management of mucinous cystic lesions of the pancreas (CLPs) and were updated in 2012 (International Consensus Guidelines, ICG 2012). This study aims to evaluate the clinical utility of the ICG 2012 with the SCG based on initial cross-sectional imaging findings. METHODS: One hundred fourteen patients with mucinous CLPs were reviewed and classified according to the ICG 2012 as high risk (HR(ICG2012)), worrisome (W(ICG2012)), and low risk (LR(ICG2012)), and according to the SCG as high risk (HR(SCG)) and low risk (LR(SCG)). RESULTS: On univariate analysis, the presence of symptoms, obstructive jaundice, elevated serum carcinoembryonic antigen (CEA)/carbohydrate antigen (CA)19-9, solid component, main pancreatic duct ≥ 10 mm, and main pancreatic duct ≥ 5 mm was associated with high grade dysplasia/invasive carcinoma in all mucinous CLPs. Increasing number of HR(SCG) or HR(ICG2012) features was associated with a significantly increased likelihood of malignancy. The positive predictive value of HR(SCG) and HR(ICG2012) for high grade dysplasia/invasive carcinoma was 46% and 62.5% respectively. The negative predictive value of both LR(SCG) and LR(ICG2012) was 100%. CONCLUSION: Both the guidelines were useful in the initial cross-sectional imaging evaluation of mucinous CLPs. The ICG 2012 guidelines were superior to the SCG guidelines.
Authors: Maria Moris; David W Dawson; Jennifer Jiang; Jason Lewis; Aziza Nassar; Kenneth K Takeuchi; Anna R Lay; Qihui Zhai; Timothy R Donahue; Kimberly A Kelly; Howard C Crawford; Michael Wallace Journal: Pancreas Date: 2016-10 Impact factor: 3.327
Authors: Michael Sighinolfi; Susan Y Quan; Yvonne Lee; Alvaro Ibaseta; Kimberly Pham; Monica M Dua; George A Poultsides; Brendan C Visser; Jeffery A Norton; Walter G Park Journal: Dig Dis Sci Date: 2017-01-23 Impact factor: 3.199
Authors: Yazan S Khaled; Muhammed Mohsin; Kavi Fatania; Ada Yee; Robert Adair; Maria Sheridan; Christian Macutkiewicz; Amer Aldouri; Andrew M Smith Journal: HPB (Oxford) Date: 2016-08-30 Impact factor: 3.647
Authors: Nadav Sahar; Anthony Razzak; Zaheer S Kanji; David L Coy; Richard Kozarek; Andrew S Ross; Michael Gluck; Michael Larsen; Shayan Irani; S Ian Gan Journal: Surg Endosc Date: 2017-12-29 Impact factor: 4.584
Authors: Albert Strauss; Matthew Birdsey; Stefan Fritz; Bogata D Schwarz-Bundy; Frank Bergmann; Thilo Hackert; Hans-Ullrich Kauczor; Lars Grenacher; Miriam Klauss Journal: Br J Radiol Date: 2016-03-09 Impact factor: 3.039